HepaStem consists of liver-derived Mesenchymal Stem Cells that are obtained from ethically healthy donated organs and expanded in the lab.
Learn in the 3D animation below about the multiple modes of action of HepaStem and why the technology is ideal to promote immune modulation and reduce tissue fibrosis for devastating immune-mediated liver diseases.
Chronic liver injury is caused by multiple hits, such as viral infection, toxic injury or excessive calory intake. NASH, is due to mainly fat accumulation leading to systemic liver inflammation, progressive fibrosis and eventually end-stage liver disease.
In additional, patients with chronic liver disease are at risk of abrupt loss of liver function, called ACLF.
Liver injury starts with hepatocyte damage triggering the process of programmed cell death. This is followed by activation of hepatic stellate cells, increased deposition of collagens together with inflammatory cell infiltration , activation and the release of pro-inflammatory cytokines.
HepaStem, administered intravenously, circulates in the body and enters the liver via the bloodstream. After reaching the liver, HepaStem has multiple modes of action and targets several altered pathways. The cells will cool down the pro-inflammatory environment, inhibit hepatic stellate cells activation and collagen secretion.
The combination of the immunomodulatory and anti-fibrotic potential builds on the tissue repair support function.
Therefore, Promethera believes that its HepaStem technology is ideal to promote immune modulation and reduce tissue fibrosis for devastating immune-mediated liver diseases.